Ilsung Pharm (003120) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.008x

Based on the latest financial reports, Ilsung Pharm (003120) has a cash flow conversion efficiency ratio of -0.008x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.10 Billion ≈ $-2.10 Million USD) by net assets (₩386.34 Billion ≈ $261.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ilsung Pharm to measure how much of total assets are equity-financed.

Ilsung Pharm - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Ilsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Ilsung Pharm to evaluate the quality of earnings relative to operating cash generation.

Ilsung Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilsung Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Arihant Capital Markets Limited NSE:ARIHANTCAP	-0.250x
Hwashin Precision Engineering Co. Ltd KQ:126640	-0.060x
Winsome Resources Ltd AU:WR1	-0.050x
Nestcon Bhd KLSE:0235	0.079x
Seanergy Maritime Holdings Corp F:RHSR	0.037x
COMMERCIAL SYN BAGS ORD (BSE) NSE:COMSYN	0.024x
Royce Global Value Trust Inc NYSE:RGT	0.001x
51 TALK ONL. SP.ADR A 60 F:C4G0	N/A

Annual Cash Flow Conversion Efficiency for Ilsung Pharm (2013–2025)

The table below shows the annual cash flow conversion efficiency of Ilsung Pharm from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 003120 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩386.34 Billion ≈ $261.82 Million	₩3.88 Billion ≈ $2.63 Million	0.010x	+190.91%
2024-12-31	₩385.13 Billion ≈ $261.00 Million	₩-4.26 Billion ≈ $-2.88 Million	-0.011x	+89.80%
2023-12-31	₩382.75 Billion ≈ $259.39 Million	₩-41.47 Billion ≈ $-28.11 Million	-0.108x	-23.91%
2022-12-31	₩445.57 Billion ≈ $301.95 Million	₩-38.97 Billion ≈ $-26.41 Million	-0.087x	-630.33%
2021-12-31	₩345.91 Billion ≈ $234.42 Million	₩5.70 Billion ≈ $3.87 Million	0.016x	+267.94%
2020-12-31	₩347.48 Billion ≈ $235.48 Million	₩1.56 Billion ≈ $1.06 Million	0.004x	-64.72%
2019-12-31	₩345.49 Billion ≈ $234.13 Million	₩4.39 Billion ≈ $2.97 Million	0.013x	-72.70%
2018-12-31	₩324.34 Billion ≈ $219.80 Million	₩15.09 Billion ≈ $10.23 Million	0.047x	+47.86%
2017-12-31	₩322.83 Billion ≈ $218.77 Million	₩10.16 Billion ≈ $6.88 Million	0.031x	+132.48%
2016-12-31	₩320.10 Billion ≈ $216.93 Million	₩-31.01 Billion ≈ $-21.02 Million	-0.097x	-610.55%
2015-12-31	₩318.34 Billion ≈ $215.74 Million	₩6.04 Billion ≈ $4.09 Million	0.019x	+48.84%
2014-12-31	₩328.68 Billion ≈ $222.74 Million	₩4.19 Billion ≈ $2.84 Million	0.013x	-18.74%
2013-12-31	₩322.74 Billion ≈ $218.72 Million	₩5.06 Billion ≈ $3.43 Million	0.016x	--

About Ilsung Pharm

KO:003120 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$92.84 Million

₩137.00 Billion KRW

Market Cap Rank

#19401 Global

#934 in Korea

Share Price

₩20100.00

Change (1 day)

-1.23%

52-Week Range

₩18300.00 - ₩28300.00

All Time High

₩31693.76